secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALX ONCOLOGY HOLDINGS INC (ALXO)
CIK:        0001810182
Form:       8-K
Filed at:   2023-09-06T23:59:59+00:00
Accession:  0001193125-23-229584
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ALX Oncology appoints Jason Lettmann as CEO; Jaume Pons becomes CSO
-------------------------------------------------------------------

- Jason Lettmann named CEO effective Sept 6, 2023; succeeds Jaume Pons who becomes President and CSO.
- Lettmann receives $675K base salary, 55% bonus target, and 1,200,000 share stock option grant.
- Pons retains $650K base salary, same bonus target, and existing equity awards unchanged.
- Lettmann brings biotech CEO (Promedior/Roche) and VC experience; Board member since 2015.
- CEO change comes as evorpacept ASPEN-06 Phase 2 data in HER2+ gastric cancer remains on track for Q4'23.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1810182/000119312523229584/0001193125-23-229584-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1810182/000119312523229584/d846509d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-229584

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer